Skip to main
  1. Stocks
  2. MeiraGTx Holdings plc
  3. Forecast
MGTX

MGTX Stock Forecast & Price Target

MGTX Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 43%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

MeiraGTx Holdings is viewed positively because it combines a differentiated clinical pipeline with meaningful non-dilutive financing, reducing near-term funding risk while preserving upside from its lead assets. The company now expects bota-vec’s FDA BLA filing in 2026 and a first commercial launch in 2027, while xerostomia is fully enrolled in Phase II with a 2Q27 readout, mid-’27 BLA filing, and early-’28 U.S. launch potential. Financially, it reported $321 million of revenue in 2Q26, ended with $145 million in cash, and said its runway extends into 2H28, supported by strategic capital from Oberland and Hologen plus in-house GMP manufacturing and proprietary vector platforms.

Bears say

MeiraGTx Holdings is a clinical-stage genetic medicines company whose valuation depends heavily on pipeline success, making it vulnerable to clinical program execution risk, regulatory uncertainty, and the possibility that key programs fail to demonstrate efficacy. Its focus on high-unmet-need diseases such as radiation-induced xerostomia, Parkinson’s disease, and AIPL1-associated retinal dystrophy does not eliminate the risk that safety signals, competition, or intellectual property disputes could delay or impair commercialization. Although its vertical integration and in-house manufacturing capabilities provide operational control, the company still faces long-term pricing pressure and remains exposed to the inherent uncertainty of advancing multiple unproven therapies from development to market.

MGTX has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 43% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MeiraGTx Holdings plc and is not a guaranteed prediction by Public.com or investment advice.

MGTX Analyst Forecast & Price Prediction

Get the latest MGTX stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in MGTX

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MeiraGTx Holdings plc (MGTX) Forecast

Analysts have given MGTX a Buy based on their latest research and market trends.

According to 7 analysts, MGTX has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $23.14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $23.14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MeiraGTx Holdings plc (MGTX)


MGTX Analyst Forecast & Price Prediction

Get the latest MGTX stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in MGTX

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover MGTX stock data and trends